Endocrine/metabolic

INDICATION: Hyperoxaluria

Mouse studies suggest CRISPR-Cas9-based gene editing therapies targeting HAO1 could help treat primary hyperoxaluria type

Read the full 178 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE